Patents Assigned to Recordati, S.A.
-
Patent number: 7267827Abstract: An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.Type: GrantFiled: July 13, 2001Date of Patent: September 11, 2007Assignee: Recordati S.A.Inventors: Giancarlo Santus, Giuseppe Bottoni, Ettore Bilato
-
Publication number: 20060148821Abstract: N,N-Disubstituted diazocycloalkanes of the formula I (R1=halogen, R2=(C3-C8)-cycloalkyl, R3=(C1-C4)-alkoxy or (C1-C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.Type: ApplicationFiled: February 27, 2006Publication date: July 6, 2006Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Patent number: 7071197Abstract: N,N-Disubstituted diazocycloalkanes of the formula I (R1=halogen, R2=(C3–C8)-cycloalkyl, R3=(C1–C4)-alkoxy or (C1–C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.Type: GrantFiled: June 16, 2003Date of Patent: July 4, 2006Assignee: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Patent number: 6953800Abstract: Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the ?1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.Type: GrantFiled: August 22, 2001Date of Patent: October 11, 2005Assignees: Recordati S.A. Chemical, Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Giorgio Sironi
-
Patent number: 6894052Abstract: Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are diarylalkylpiperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT1A receptors, for treating disorders of the lower urinary tract.Type: GrantFiled: July 31, 1998Date of Patent: May 17, 2005Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Publication number: 20040215284Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agent for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal.Type: ApplicationFiled: January 29, 2004Publication date: October 28, 2004Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Rodolfo Testa, Elena Poggesi
-
Publication number: 20040171666Abstract: An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.Type: ApplicationFiled: March 2, 2004Publication date: September 2, 2004Applicant: Recordati S.A., Chemical and Pharmaceutical Company, A corporation of SwitzerlandInventors: Giancarlo Santus, Giuseppe Bottoni, Ettore Bilato
-
Patent number: 6680319Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: GrantFiled: January 17, 2002Date of Patent: January 20, 2004Assignee: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Publication number: 20030181446Abstract: Described are novel N-acylated heterocycle derivatives having affinity for serotonergic receptors. These compounds and their enantiomers, diastercoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.Type: ApplicationFiled: October 7, 2002Publication date: September 25, 2003Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Carlo Riva, Jeffrey Corbett
-
Publication number: 20030162777Abstract: Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptors.Type: ApplicationFiled: October 7, 2002Publication date: August 28, 2003Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Carlo Riva, Jeffrey W. Corbett, Per-Olof Andersson
-
Patent number: 6583287Abstract: A process for the production of paroxetine is described, wherein N-substituted derivatives of 4-(p-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine are treated according to the following sequence of reactions: (a) hydrogenation catalyzed by transition metal complexes with chiral diphosphinic ligands; (b) —OH derivatisation and nucleophilic substitution, the substituent being sesamol; (c) N-dealkylation. The process is highly stereospecific and brings about the formation of intermediates enriched with the desired isomeric components, which are converted into paroxetine in quantitative yields.Type: GrantFiled: July 30, 2001Date of Patent: June 24, 2003Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Renzo Rossi, Stefano Turchetta, Maria Donnarumma
-
Publication number: 20020193383Abstract: The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.Type: ApplicationFiled: April 22, 2002Publication date: December 19, 2002Applicant: Recordati S.A., Chemical and Pharmaceutical ComoanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Publication number: 20020193381Abstract: The invention is directed to compounds of Formula I: 1Type: ApplicationFiled: August 16, 2001Publication date: December 19, 2002Applicant: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Publication number: 20020183290Abstract: Described are derivatives with an adrenergic antagonistic activity and, in particular, high selectivity for &agr;1a- and &agr;1d-adrenergic receptors compared to &agr;1b-receptors. This selectivity profile suggests the use of these derivatives in the treatment of symptoms of the lower urinary tract, including those associated to benign prostatic hyperplasia, without the side effects associated with hypotensive activity.Type: ApplicationFiled: January 30, 2002Publication date: December 5, 2002Applicant: Recordati S.A., Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa
-
Patent number: 6486163Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(5-substituted-7-oxo-7H-thieno[3,2-b]pyran-3-carbonylamino)alkyl]piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neutogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: GrantFiled: August 16, 2001Date of Patent: November 26, 2002Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Publication number: 20020161012Abstract: The invention relates to novel N-(substituted phenyl)-N′-[(&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: ApplicationFiled: January 17, 2002Publication date: October 31, 2002Applicant: RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANYInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Publication number: 20020161009Abstract: Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &agr;1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.Type: ApplicationFiled: August 22, 2001Publication date: October 31, 2002Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Giorgio Sironi
-
Patent number: 6440963Abstract: The treatment of neuromuscular dysfunction of the lower urinary tract by compounds which selectively inhibit the COX-2 isozyme is described. The compounds concerned inhibit the COX-2 isozyme with a potency at least 10-fold, and preferably at least 100-fold, greater than their potency on the COX-1 isozyme.Type: GrantFiled: October 1, 2001Date of Patent: August 27, 2002Assignee: Recordati S.A., Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Rodolfo Testa, Luciano Guarneri
-
Publication number: 20020077346Abstract: An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.Type: ApplicationFiled: July 13, 2001Publication date: June 20, 2002Applicant: RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANYInventors: Giancarlo Santus, Giuseppe Bottoni, Ettore Bilato
-
Patent number: 6403594Abstract: The invention relates to novel benzopyran derivatives of formula I, their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS), neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.Type: GrantFiled: October 18, 2000Date of Patent: June 11, 2002Assignee: Recordati, S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Giorgio Sironi